Randal J. Kirk

Last updated
Randal J. Kirk
Born (1954-03-01) March 1, 1954 (age 68) [1]
Pleasanton, California, U.S.
Alma mater Radford University (BA, 1976) [2]
University of Virginia School of Law (JD, 1979) [3]
Occupation Biotech investor; CEO of Intrexon Corporation; founder and senior managing director of Third Security, LLC
Known forBiotech investing [4]
Political party Independent [5]
Board member of
  • Intrexon Corporation (since 2008)
  • Halozyme Therapeutics (since 2007)
Children4 [6]

Randal J. Kirk [7] [5] (born March 1, 1954) is an American businessman and investor in pharmaceuticals and biotechnology. Kirk was the chairman and chief executive officer of Intrexon (NYSE: XON), a biotechnology company, until 2020. Kirk started as a lawyer, but is best known for his investments in pharmaceutical and biotech companies. In addition to high-profile sales of New River Pharmaceuticals, Inc., and Clinical Data, Inc, Kirk also founded investment firm Third Security, LLC, and has held board seats with biotech companies, such as Scios, Inc. He is a billionaire. [3]

Contents

Early life and education

Randal J. Kirk was born in Pleasanton, California. [8] The son of a U.S. Air Force master sergeant, [9] Kirk and his family moved from California to Texas before settling in Virginia. [8] Kirk graduated from Pulaski High School in Pulaski County, Virginia. [5] Following high school, Kirk worked selling cars and motorcycles, and enrolled part-time at Radford University to study business. [5] He earned a bachelor's degree in Economics at Radford in 1976, followed by a Juris Doctor at the University of Virginia in 1979. [6]

Career

Kirk was admitted to the bar in 1980, becoming the only attorney in Bland, Virginia, and began a practice he ran until 1990. [7] [8] [2] In 1983, he partnered with Bland County pharmacist John Gregory to found the next-day pharmaceutical distributor General Injectables and Vaccines. Kirk and his partners would go on to sell the business to Henry Schein, Inc. for $65 million in 1998. [9] [10] [11]

In 1996, Kirk founded New River Pharmaceuticals, where he served as chairman and CEO and took the company public in 2004. [12] [13] The developer of attention-deficit drug Vyvanse, New River would prove to be Kirk's single biggest payoff when he sold the company to Shire in 2007 for $2.6 billion, making over a $1 billion for Kirk himself. [7] [14]

In 1999, Kirk founded the life-sciences investment firm Third Security, LLC, where he is senior managing director, CEO and chairman. [15] [16] From 2000 to 2002, Kirk served as a member of the board of directors for Scios, Inc., a maker of heart disease medication that later sold to Johnson & Johnson for $2.4 billion. [17] [18] Kirk also became the majority stock holder and chairman of Newton, Massachusetts-based pharmaceutical company Clinical Data, Inc. In 2011, shortly after Clinical Data's drug Viibryd received regulatory approval, Forest Laboratories bought Clinical Data for $1.2 billion. [19]

Kirk became involved with biotechnology company Intrexon in the 2000s. He was named chairman of its board in 2008 and became CEO in 2009. [20] Kirk took Intrexon public in 2013, taking the company's market cap to $2.5 billion with the IPO. [21] In early 2020, Intrexon adopted the name of its subsidiary, Precigen, and narrowed its focus to human gene editing. [22] [23] With the change in name the CEO of subsidiary Precigen, Helen Sabzevari, took over leadership of the company from Kirk. [24]

Intrexon sold AquaBounty [25] to TS Aquaculture, LLC, a privately held company managed by Third Security, LLC, a venture capital firm led by former Intrexon Chairman & CEO Randal Kirk. [26] In addition to AquaBounty's development of genetically modified salmon, Kirk is involved in other companies advocating the approval of genetic engineering, including disease-resistant mosquitoes [27] and an apple which resists browning. [28] Other projects of Kirk's companies include creating cancer treatments, gasoline substitutes, crop protection, and improving bovine genetics. [7] [29] [30]

Recognition

Kirk has been profiled by SynBioBeta and Forbes. [31] [32] In 2008, Virginia Gov. Tim Kaine named Kirk Virginia's Outstanding Industrialist for the Year. [33] He has spoken at the SynBioBeta Conference, [31] BioFlorida, [34] Klick Ideas Exchange [35] and was a Borlaug Dialogue Speaker at the World Food Prize. [36]

Philanthropy and other roles

Following the sale of General Injectables and Vaccines, Kirk donated $1 million to Radford University, creating the Zylphia Shu-En Kirk Endowment [5] named after his daughter. [2] Kirk has served on the board of directors of the Radford University Foundation and the school's board of visitors. [5] Kirk was a member of University of Virginia's board of visitors from 2009 to 2012. [37]

Kirk has also donated substantially to political causes. He considers himself a political independent, and has supported both Republicans and Democrats. [38] He has been especially involved in Virginia politics, donating $1.8 million to candidates for state office, including $200,000 to Terry McAuliffe's 2009 Virginia gubernatorial election. [39] [40]

Personal life

Kirk lives in West Palm Beach, Florida and has four children. [7] According to Forbes, Kirk is worth $2.0 billion and ranks No. 1135 on its billionaires list. [3] Kirk's hobbies include falconry. [41]

Related Research Articles

Radford University University in Virginia, USA

Radford University is a public university in Radford, Virginia. It is one of the state's eight doctorate-granting public universities. Founded in 1910, Radford offers curricula for undergraduates in more than 100 fields, graduate programs including the M.F.A., M.B.A., M.A., M.S., Ed.S., Psy.D., M.S.W., and specialized doctoral programs in health-related professions. It is classified among "Doctoral/Professional Universities".

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.

Ernesto Bertarelli Swiss-Italian billionaire

Ernesto Silvio Maurizio Bertarelli is an Italian-born Swiss billionaire businessman and philanthropist.

Dilip Shanghvi Indian Businessman

Dilip Shanghvi is an Indian billionaire businessman and one of the country's richest people. He founded Sun Pharmaceuticals. The Government of India awarded him the civilian honour of the Padma Shri in 2016. India Today magazine ranked him 8th in India's most powerful people of 2017 list.

Biocon Indian multinational biopharmaceutical company

Biocon Limited is an Indian biopharmaceutical company that is based in Bangalore, India. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in over 120 countries across the globe, including the developed markets of the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets. Syngene International Limited (Syngene) is a publicly listed subsidiary of Biocon, operating in the contract research services space.

Bausch Health Companies Inc. is a Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products.

Regeneron Pharmaceuticals American biotechnology company

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.

Nelson Peltz is an American billionaire businessman and investor. He is a founding partner, together with Peter W. May and Edward P. Garden, of Trian Fund Management, an alternative investment management fund based in New York. He is non-executive chairman of Wendy's Company, Sysco, and The Madison Square Garden Company. He is a former director of H.J. Heinz Company, Mondelēz International, and Ingersoll Rand and a former CEO of Triangle Industries.

Fred Hassan, is a Pakistan-born American business executive who works for Warburg Pincus and was CEO of three global pharmaceutical companies.

Heather Bresch American business executive

Heather Manchin Bresch is an American business executive. In 2012, she was named as the chief executive officer (CEO) of Netherlands-based pharmaceutical company Mylan, becoming the first woman to run a Fortune 500 pharmaceutical company. Bresch retired in 2020, upon the closing of Mylan’s combination with Upjohn. Bresch has been a central figure in two controversies: a 2007 accusation of inflating her resume with an unearned MBA degree, and as the CEO of Mylan during the 2016 controversy over pricing of the company's EpiPen products. In 2015, she was listed as #22 in Fortune magazine's “Most Powerful Women” list.

Patrick Soon-Shiong Chinese- African American billionaire physician, CEO & philanthropist

Patrick Soon-Shiong is a Chinese-South African transplant surgeon, billionaire businessman, bioscientist, and media proprietor. He is the inventor of the drug Abraxane, which became known for its efficacy against lung, breast, and pancreatic cancer. Soon-Shiong is the founder of NantWorks, a network of healthcare, biotech, and artificial intelligence startups; an adjunct professor of surgery and executive director of the Wireless Health Institute at the University of California, Los Angeles; and a visiting professor at Imperial College London and Dartmouth College. Soon-Shiong has published more than 100 scientific papers and has more than 230 issued patents worldwide on advancements spanning numerous fields in technology and medicine.

ARIAD Pharmaceuticals Defunct oncology company

ARIAD Pharmaceuticals, Inc. was an American oncology company, now part of Takeda Oncology, which was founded in 1991 by Harvey J. Berger, M.D. and headquartered in Cambridge, Massachusetts. ARIAD engaged in the discovery, development, and commercialization of medicines for cancer patients.

Phillip Frost is an American entrepreneur.

Galena Biopharma

Galena Biopharma was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc.

David Kalergis

David Kalergis is an American life sciences entrepreneur and the Co-founder, Chairman and Chief Executive Officer of Diffusion Pharmaceuticals Inc, a Charlottesville, Virginia, U.S.-based biotechnology and pharmaceutical company. He co-founded the company in 2001 with American chemical engineer John L. Gainer. Kalergis became Diffusion's CEO in 2004, a position in which he has drawn extensively on his career in law, business, and clinical trials implementation. Under Kalergis' leadership, Diffusion Pharmaceuticals has been cited for advancing improved cancer treatments and is currently conducting multicenter clinical trials of a novel therapeutic for brain cancers, including glioblastoma multiforme. Diffusion Pharmaceuticals is also currently conducting clinical trials for the treatment of oxygen deficiencies associated with COVID-19 and acute stroke.

Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Robert Duggan (venture capitalist) American businessman and prominent Scientologist

Robert W. Duggan is an American billionaire, entrepreneur, philanthropist, biotech executive, health care executive, educator, and human rights activist. He is the former CEO of biopharmaceutical company Pharmacyclics and was previously CEO of surgical systems maker Computer Motion from 1997 to 2003. Bob is the majority shareholder and currently serves on the Boards of Directors of Pulse Biosciences and Summit Therapeutics, where he also serves as CEO.

Vinita D. Gupta is an Indian businesswoman, the chief executive officer (CEO) of Lupin Limited since September 2013, and the chairperson of Lupin Inc (LI), and its US subsidiary, Lupin Pharmaceuticals Inc (LPI).

Precigen

Precigen, Inc is an American biotechnology company. Its president and CEO is Helen Sabzevari.

References

  1. ↑ "The World's Billionaires". Forbes. March 2013. Archived from the original on 25 April 2013. Retrieved 24 April 2013.
  2. 1 2 3 "R.J. Kirk". RU Magazine. Radford University. May 1999. Archived from the original on 3 April 2013. Retrieved 20 January 2017.
  3. 1 2 3 "Forbes #1135 Randal Kirk". Forbes 400 . Retrieved 18 November 2020.
  4. ↑ Langreth, Robert; Herper, Matthew (22 February 2011). "The Next Big Move For The Smartest Biotech Investor". Forbes . Retrieved 25 April 2013.
  5. 1 2 3 4 5 6 Manese-Lee, Angela (20 February 2007). "Meet Randal J. Kirk, Southwest Virginia's first billionaire". The Roanoke Times . Retrieved 20 January 2017.
  6. 1 2 "Randal Kirk". Forbes . Archived from the original on 8 May 2013. Retrieved 24 April 2013.
  7. 1 2 3 4 5 Pollack, Andrew (5 March 2016). "A biotech evangelist". The New York Times . Retrieved 20 January 2017.
  8. 1 2 3 Greenberg, Duncan (22 September 2007). "Flying solo". Forbes . Retrieved 20 January 2017.
  9. 1 2 "The 400 Richest Americans". Forbes 400 . 17 September 2008. Archived from the original on 18 March 2017. Retrieved 20 January 2017.
  10. ↑ "Following the smart money: The small cap biotech investments of Randal J. Kirk". Seeking Alpha . 11 March 2014. Retrieved 23 January 2017.
  11. ↑ "Henry Schein To Acquire VA-Based Marketer Of Injectables And Vaccines". Pharmaceutical Online. 5 January 1999. Retrieved 24 April 2013.
  12. ↑ "Randal Kirk". Reuters. Archived from the original on 9 June 2016. Retrieved 23 January 2017.
  13. ↑ "New River closes $30mm IPO". 1 August 2004. Retrieved 25 April 2013.
  14. ↑ "Randal "RJ" Kirk". FierceBiotech. 4 April 2013. Retrieved 31 January 2017.
  15. ↑ Mintz, Cliff (9 June 2011). "Through the eyes of a billionaire life sciences investor". Life Science Leader. Retrieved 23 January 2017.
  16. ↑ "Our people". Third Security, LLC. Retrieved 23 January 2017.
  17. ↑ Sturgeon, Jeff (18 December 2004). "R.J. Kirk's prescription for success: Staying busy". The Roanoke Times . Retrieved 23 January 2017.
  18. ↑ Hensley, Scott; Sidel, Robin (11 February 2003). "Johnson & Johnson agrees to buy Scios for $2.4 billion". The Wall Street Journal . Retrieved 23 January 2017.
  19. ↑ Clarke, Toni (22 February 2011). "Forest Labs to acquire Clinical Data for $1.2 billion". Reuters . Retrieved 23 January 2017.
  20. ↑ "Board of directors: Randal J. Kirk". Intrexon. Retrieved 23 January 2017.
  21. ↑ Solomon, Brian (9 August 2013). "Biotech billionaire Randal Kirk nets $1.5 billion windfall on Intrexon IPO". Forbes . Retrieved 23 January 2017.
  22. ↑ "INTREXON CORPORATION IS NOW PRECIGEN, INC". Precigen . Retrieved 6 April 2020.
  23. ↑ Helmstetter, Michael (30 March 2020). "The Promise And Fear Of Gene Editing". Forbes . Retrieved 6 April 2020.
  24. ↑ Gilgore, Sara (6 January 2020). "Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug". American City Business Journals . Retrieved 6 April 2020.
  25. ↑ Pollack, Andrew (19 November 2015). "Genetically engineered salmon approved for consumption". The New York Times . Retrieved 23 January 2017.
  26. ↑ House, Douglas G (31 October 2019). "Intrexon sells AquaBounty stake to CEO-affiliated aquaculture business". Seeking Alpha. Retrieved 2 December 2020.
  27. ↑ "Press Release: Intrexon to acquire Oxitec, pioneer of innovative insect control solutions addressing global challenges". Oxitec. 10 August 2015. Retrieved 16 March 2017.
  28. ↑ Rebecca Randall (4 March 2015). "Synbio firm Intrexon snaps up Okanagan, developers of new GM Arctic Apple". Genetic Literacy Project. Retrieved 16 March 2017.
  29. ↑ Kunzig, Robert (16 October 2014). "Cloning cows from steaks (and other ways of building better cattle)". National Geographic . Retrieved 31 January 2017.
  30. ↑ Maxx Chatsko (6 September 2016). "Intrexon investors are neglecting this technology platform". The Motley Fool . Retrieved 31 January 2017.
  31. 1 2 Christopher Harrison (28 October 2015). "From BIOtech to bioTECH: Meet Serial Entrepreneur Randal Kirk, CEO of Intrexon". SynBioBeta. Retrieved 23 January 2017.
  32. ↑ Herper, Matthew (22 February 2011). "Is Randal J. Kirk biotech's best investor?". Forbes . Retrieved 23 January 2017.
  33. ↑ "The Virginia 100". VirginiaBusiness.com. 1 June 2008. Retrieved 23 January 2017.
  34. ↑ Manning, Margie (17 September 2013). "Biotech entrepreneur says industry falls short of potential". Tampa Bay Business Journal . Retrieved 23 January 2017.
  35. ↑ "Drs. Eric Topol, Daniel Kraft & Ezekiel Emanuel, Biotech's Martine Rothblatt, Craig Venter & RJ Kirk, business gurus Gary Hamel & Tom Peters, along with other visionaries to speak at Klick Ideas Exchange". Klick Ideas Exchange. 10 June 2015. Retrieved 23 January 2017.
  36. ↑ "2016 Borlaug Dialogue Speakers". The World Food Prize . Retrieved 23 January 2017.
  37. ↑ "Randal J. Kirk resigns from UVa board". The Associated Press. 6 October 2012. Retrieved 23 January 2017.
  38. ↑ Manese-Lee, Angela; Paul Dellinger (February 20, 2007). "Meet Randal J. Kirk, Southwest Virginia's first billionaire". Roanoke Times. Retrieved March 16, 2017.
  39. ↑ Meola, Olympia; Tyler Whitley (April 17, 2009). "Bill Clinton, Trump among McAuliffe's donors". Richmond Times Dispatch. Richmond, Virginia. Retrieved March 16, 2017.
  40. ↑ "Money Out (Contributions): Randal J Kirk". Virginia Public Access Project. Retrieved 2009-04-22.
  41. ↑ Milligan, Jack (June 2006). "The 2006 Virginia 100 - Feathering his nest - Randal J. Kirk builds companies and fortunes". Virginia Business Magazine. Archived from the original on April 7, 2009. Retrieved 2009-04-22.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.